-continued

```
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
            180                 185                 190

Gly Asn Val Phe Ser Cys Ser Val Met His Gly Ala Leu His Asn His
        195                 200                 205

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
    210                 215                 220
```

1. An antigen-binding molecule, optionally isolated, comprising an Fc region, the Fc region comprising a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) one or more of: A at the position corresponding to position 236, D at the position corresponding to position 239, E at the position corresponding to position 332, L at the position corresponding to position 330, K at the position corresponding to position 345, and G at the position corresponding to position 430.

2. The antigen binding molecule according to claim **1**, wherein the Fc region comprises a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) A at the position corresponding to position 236, D at the position corresponding to position 239, E at the position corresponding to position 332, and L at the position corresponding to position 330;

or A at the position corresponding to position 236, D at the position corresponding to position 239, and E at the position corresponding to position 332; or A at the position corresponding to position 236, and D at the position corresponding to position 239; or K at the position corresponding to position 345, and G at the position corresponding to position 430.

3. The antigen binding molecule according to claim **1** or claim **2**, wherein the Fc region comprises a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) A at the position corresponding to position 236, D at the position corresponding to position 239, E at the position corresponding to position 332, and L at the position corresponding to position 330.

4. The antigen binding molecule according to claim **1** or claim **2**, wherein the Fc region comprises a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) A at the position corresponding to position 236, D at the position corresponding to position 239, and E at the position corresponding to position 332.

5. The antigen binding molecule according to claim **1** or claim **2**, wherein the Fc region comprises a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) A at the position corresponding to position 236, and D at the position corresponding to position 239.

6. The antigen binding molecule according to claim **1** or claim **2**, wherein the Fc region comprises a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) K at the position corresponding to position 345, and G at the position corresponding to position 430.

7. The antigen binding molecule according to any one of claims **1** to **6**, wherein the Fc region comprises a polypeptide comprising an amino acid sequence having at least 60% sequence identity to SEQ ID NO:39, 38, 37, 41, 22, 21, 20 or 24.

8. A polypeptide, optionally isolated, comprising: an amino acid sequence having at least 60% sequence identity to SEQ ID NO:31 or 6, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) one or more of: A at position 9, D at position 12, L at position 103, E at position 105, K at position 118, and G at position 203.

9. The polypeptide according to claim **8**, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) A at position 9, D at position 12, L at position 103, and E at position 105; or A at position 9, D at position 12, and E at position 105; or A at position 9, and D at position 12; or K at position 118, and G at position 203.

10. The polypeptide according to claim **8** or claim **9**, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) A at position 9, D at position 12, L at position 103, and E at position 105.

11. The polypeptide according to claim **8** or claim **9**, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) A at position 9, D at position 12, and E at position 105.

12. The polypeptide according to claim **8** or claim **9**, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) A at position 9, and D at position 12.

13. The polypeptide according to claim **8** or claim **9**, wherein the polypeptide comprises the following amino acid residues at the specified positions numbered relative to SEQ ID NO:31 or 6: (i) C at position 15, and C at position 107, and (ii) K at position 118, and G at position 203.

14. A polypeptide, optionally isolated, comprising the amino acid sequence of SEQ ID NO:39, 38, 37, 41, 22, 21, 20 or 24.

15. An Fc region, optionally isolated, comprising a polypeptide according to any one of claims **8** to **14**.

16. An antigen-binding molecule, optionally isolated, comprising a polypeptide according to any one of claims **7** to **13**, or an Fc region according to claim **14**.

17. A nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule accord-